

Analytical Study on Certain Mixtures Containing Polyionic Drugs

Thesis

**Presented for The Doctor of Philosophy Degree
in Pharmaceutical Sciences
(Pharmaceutical Analytical Chemistry)**

By

Noha Morsy Ibrahim El Zahar

**B.SC. Pharmaceutical Sciences 2010
Master Pharmaceutical Sciences (Pharmaceutical Analytical
Chemistry) 2014**

**Faculty of Pharmacy
Ain Shams University**

Under the Supervision of

Prof. Dr. Amira Mabrouk El-Kosasy

**Professor of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy, Ain Shams University**

Prof. Dr. Michael Griffith Bartlett

**Professor of Pharmaceutical and Biomedical Sciences,
Associate Dean for Science Education, Research and Technology,
College of Pharmacy, University of Georgia**

The late Dr. Omar Abdel-Aziz Ali Ghonim

**Associate Professor of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy, Ain Shams University**

Dr. Nancy Magdy Hana

**Associate Professor of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy, Ain Shams University**

**Pharmaceutical Analytical Chemistry Department
Faculty of Pharmacy, Ain Shams University
2018**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

((قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ))

صدق الله العظيم

سورة البقرة آية (٣٣)

ACKNOWLEDGEMENT

All thanks and gratitude is to my lord Allah, who has given me the strength and will to finish this work. Words and thanks will never suffice to praise Allah for his mercy, blessings and guidance that lead me through the tough times.

I would like to express my deepest gratitude and sincere appreciation to **Prof. Dr. Amira Mabrouk El-Kosasy**, Professor of Pharmaceutical Analytical Chemistry department, Faculty of Pharmacy, Ain Shams University, for her kind and expert supervision, patience, unlimited support, generous assistance and for the extensive effort, time and energy. I will always be indebted to her kindness and continuous encouragement. No words can describe my gratitude to her. It's really an honor to be one of her students.

My profound thanks to **Prof. Dr. Michael Griffith Bartlett**, Georgia Athletic Association Professor in Pharmacy and Associate Dean For Science Education, Research and Technology, College of Pharmacy, University of Georgia, Athens, GA, USA, for his sincere guidance, endless support, valuable opinions and constructive comments that enriched this work. I really appreciate the time I spent in his lab. No words can describe my gratitude to him. It's really an honor to be one of his students.

My sincere appreciation to **Associate Prof. Dr. Omar Abdel-Aziz**, Associate Professor of Pharmaceutical Analytical Chemistry department, Faculty of Pharmacy, Ain Shams University, who, although no longer with us, was always supporting me with great patience, constructive advice, continuous encouragement and valuable assistance throughout the work. It's really an honor to be one of his students.

I would like to express my gratefulness to **Dr. Nancy Magdy Hana**, Associate Professor of Pharmaceutical Analytical Chemistry department, Faculty of Pharmacy, Ain Shams University, for her supervision, valuable assistance, priceless guidance and fruitful opinions throughout the whole practical work. It's really an honor to be one of her students.

I am very grateful to my **Father, Sisters** and especially my dear **Mother** for standing by me in every step, for their praying, their continuous support and encouragement all the way through and giving me all the strength and faith more than I needed.

Also, I would like to thank ***The Egyptian Joint Supervision Missions Department, Ministry of Higher Education, Cairo, Egypt*** for the financial support that put this work in the present form.

My sincere appreciation and thanks go to all my ***colleagues and staff members in Analytical Chemistry Department, Faculty of Pharmacy, Ain Shams University*** for their friendly cooperation and constant support.

Finally, I am greatly thankful to my ***lab colleagues in the Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, USA***, for their help and support.

***Noha Morsy El Zahar
2018***

Contents

Part I: General Introduction and Literature Review

Section A: Introduction

I.A.1. Polyionic Compounds.....	1
1.A.2. Physicochemical Properties of Polyions	1
1.A.3. Classifications of Polyionic Compounds	4

Section B: Literature review

I.B.1. Therapeutic Oligonucleotides (OGNs)	8
I.B.1.1. Structure	8
I.B.1.2. Properties	9
I.B.1.3. Pharmacology	11
I.B.1.4. Pharmacokinetics	13
I.B.1.5. Methods of analysis	13
I.B.1.5.1. Electrophoresis.....	13
I.B.1.5.2. Liquid chromatographic methods	19
I.B.1.5.3. Mass spectrometry	33
I.B.2. Tianeptine sodium (TIA)	38
I.B.2.1. Structure.....	38
I.B.2.2. Properties	38
I.B.2.3. Pharmacology	39
I.B.2.4. Pharmacokinetics	40
I.B.2.5. Methods of analysis	40
I.B.2.5.1. Spectroscopic methods.....	40
I.B.2.5.1.1. Spectrophotometric methods	40
I.B.2.5.1.2. Spectrofluorimetric methods.....	41
I.B.2.5.2. Electrochemical methods	42
I.B.2.5.3. Liquid chromatographic methods	42

Contents

I.B.3. Cilastatin sodium (CIL)	45
I.B.3.1. Structure	45
I.B.3.2. Properties	45
I.B.3.3. Pharmacology	46
I.B.3.4. Pharmacokinetics	47
I.B.3.5. Methods of analysis	47
I.B.3.5.1. Spectrophotometric methods	47
I.B.3.5.2. Electrophoresis.....	48
I.B.3.5.3. Liquid chromatographic methods	48
I.B.4. Enoxaparin sodium (ENOX).....	51
I.B.4.1. Structure	51
I.B.4.2. Properties	51
I.B.4.3. Pharmacology	52
I.B.4.4. Pharmacokinetics	52
I.B.4.5. Methods of analysis	53
I.B.4.5.1. Electrophoresis.....	53
I.B.4.5.2. Liquid chromatographic methods	54

Part II: Chromatographic Determinations of Certain Polyionic Drugs

Section A: Degradation Products Characterization of Therapeutic Antisense Oligonucleotides Using Ultra Performance Liquid Chromatography Mass Spectrometry (UPLC-MS/MS)

II.A.1. Introduction	56
II.A.2. Experimental	59
II.A.2.1. Apparatus.....	59
II.A.2.2. Materials	60
II.A.2.2.1. Pure Standards.....	60
II.A.2.2.2. Reagents	61
II.A.2.2.3. Standard solutions	61

Contents

II.A.2.3. Procedure.....	62
II.A.2.3.1. Preparation of working solutions for the degradation study	62
II.A.2.3.2. Chromatographic conditions	62
II.A.2.3.3. MS conditions.....	63
II.A.3. Results and Discussion.....	63
II.A.3.1. Effect of pH at 45°C and 90°C.....	65
II.A.3.1.1. Effect of chemical modifications on PS OGNs stability.....	68
II.A.3.1.2. Effect of length on PS OGNs stability	68
II.A.3.1.3. Sequence-dependent degradation of PS OGNs.....	69
II.A.3.2. Effect of different concentrations of hydrogen peroxide	69
II.A.4. Conclusions	71

Section B: Determinations of Tianeptine Sodium in Tablets Using LC-MS/MS

II.B.1. Introduction	96
II.B.2. Experimental.....	96
II.B.2.1. Apparatus.....	96
II.B.2.2. Materials	96
II.B.2.2.1. Pure Standards	96
II.B.2.2.2. Pharmaceutical formulation.....	97
II.B.2.2.3. Reagents.....	97
II.B.2.2.4. Standard solutions.....	97
II.B.2.3. Procedure	98
II.B.2.3.1. Chromatographic conditions.....	98
II.B.2.3.2. MS conditions.....	98
II.B.2.3.3. Method validation.....	99
II.B.2.3.3.1. Linearity.....	99
II.B.2.3.3.2. Accuracy	99
II.B.2.3.3.3. Precision	99
II.B.2.3.3.3.1. Repeatability (Intraday Precision).....	99
II.B.2.3.3.3.2. Intermediate Precision (Interday Precision)	100

Contents

II.B.2.3.3.4. Limit of detection (LOD) and limit of quantification (LOQ).....	100
II.B.2.3.3.5. Robustness	100
II.B.2.3.4. Application to pharmaceutical formulation	101
II.B.3. Results and Discussion	101
II.B.3.1. Analytical characteristics and method validation	102
II.B.3.1.1. Range and linearity	102
II.B.3.1.2. Accuracy	103
II.B.3.1.3. Precision	103
II.B.3.1.4. LOD and LOQ	104
II.B.3.1.5. Robustness	104
II.B.3.2. Statistical analysis of the results	104
II.B.4. Conclusions	104

Section C: Simultaneous Determination of Tianeptine Sodium and Its Active Metabolite Tianeptine Sodium MC5 in Rat Plasma and Brain Tissue Using LC-MS/MS

II.C.1. Introduction	111
II.C.2. Experimental.....	111
II.C.2.1. Apparatus.....	111
II.C.2.2. Materials	112
II.C.2.2.1. Pure Standards	112
II.C.2.2.2. Reagents.....	112
II.C.2.2.3. Standard solutions.....	112
II.C.2.2.4. Spiked samples	113
II.C.2.3. Procedure	113
II.C.2.3.1. Chromatographic conditions.....	113
II.C.2.3.2. MS conditions.....	114
II.C.2.3.3. Sample preparation	114
II.C.2.3.4. Method validation.....	115
II.C.2.3.4.1. Selectivity	115
II.C.2.3.4.2. Linearity.....	115

Contents

II.C.2.3.4.3. Accuracy	115
II.C.2.3.4.4. Precision	116
II.C.2.3.4.4.1. Repeatability (Intraday Precision)	116
II.C.2.3.4.4.2. Intermediate Precision (Interday Precision)	116
II.C.2.3.4.5. Recovery	116
II.C.2.3.4.6. Stability	116
II.C.2.3.4.7. Dilution test	117
II.C.2.3.4.8. Robustness	117
II.C.2.3.5. Animal study.....	117
II.C.3. Results and Discussion	118
II.C.3.1. Sample preparation and method development.....	118
II.C.3.2. LC–MS/MS method development.....	119
II.C.3.3. Analytical characteristics and method validation	120
II.C.3.3.1. Selectivity	120
II.C.3.3.2. Range and linearity	121
II.C.3.3.3. Accuracy	122
II.C.3.3.4. Precision	122
II.C.3.3.5. Recovery	122
II.C.3.3.6. Stability.....	123
II.C.3.3.7. Dilution test	124
II.C.3.3.8. Robustness	124
II.C.3.4. Applications to rat plasma and brain tissue	125
II.C.3.5. Statistical analysis of the results	126
II.C.4. Conclusions	126

Section D: Simultaneous Determination of Cilastatin Sodium, Imipenem, Paracetamol and Caffeine Using High Performance Liquid Chromatography with Diode Array Detector (HPLC-DAD)

II.D.1. Introduction	138
II.D.2. Experimental	138
II.D.2.1. Apparatus.....	138

Contents

II.D.2.2. Materials	139
II.D.2.2.1. Pure Standards	139
II.D.2.2.2. Pharmaceutical formulation	139
II.D.2.2.3. Reagents	139
II.D.2.2.4. Standard solutions	139
II.D.2.3. Procedure.....	140
II.D.2.3.1. Chromatographic conditions	140
II.D.2.3.2. Method validation.....	140
II.D.2.3.2.1. Linearity	140
II.D.2.3.2.2. Accuracy.....	141
II.D.2.3.2.3. Precision	141
II.D.2.3.2.3.1. Repeatability (Intraday Precision).....	141
II.D.2.3.2.3.2. Intermediate Precision (Interday Precision)	141
II.D.2.3.2.4. Selectivity.....	142
II.D.2.3.2.5. LOD and LOQ.....	142
II.D.2.3.2.6. Robustness.....	142
II.D.2.3.3. Application of the proposed procedure for the determination of CIL and IMP in their pharmaceutical formulation.....	142
II.D.2.3.4. Application to human urine	143
II.D.3. Results and Discussion.....	143
II.D.3.1. Analytical characteristics and method validation.....	144
II.D.3.1.1. Range and linearity.....	144
II.D.3.1.2. Accuracy.....	145
II.D.3.1.3. Precision	145
II.D.3.1.4. Selectivity	146
II.D.3.1.5. LOD and LOQ.....	146
II.D.3.1.6. Robustness	146
II.D.3.1.7. System suitability	146
II.D.3.2. Statistical analysis of the results.....	147
II.D.4. Conclusions	147

Part III: Spectrophotometric and Chemometric Determinations of Certain Polyionic Drugs

Section A: Extended Derivative Ratio Technique for The Determination of Cilastatin Sodium, Imipenem, Ciprofloxacin Hydrochloride, Dexamethasone Sodium Phosphate and Paracetamol in Human Urine

III.A.1. Introduction	159
III.A.2. Theoretical Background of EDR method.....	161
III.A.3. Experimental	164
III.A.3.1. Apparatus	164
III.A.3.2. Materials.....	164
III.A.3.2.1. Pure Standards.....	164
III.A.3.2.2. Reagents	164
III.A.3.2.3. Standard solutions	164
III.A.3.3. Procedure	165
III.A.3.3.1. Spectral characteristics of CIL, IMP, CIPRO, DEX and PAR	165
III.A.3.3.2. Derivative Ratio Spectra of CIL, IMP, CIPRO, DEX and PAR.....	165
III.A.3.3.3. Method Validation	167
III.A.3.3.3.1. Linearity	167
III.A.3.3.3.2. Accuracy	167
III.A.3.3.3.3. Precision.....	167
III.A.3.3.3.3.1. Repeatability (Intraday Precision)	167
III.A.3.3.3.3.2. Intermediate Precision (Interday Precision).....	168
III.A.3.3.3.4. Selectivity.....	168
III.A.3.3.3.5. LOD and LOQ	168
III.A.3.3.4. Application to human urine.....	169
III.A.4. Results and Discussion.....	169
III.A.4.1. Spectral Characteristics of the studied compounds.....	169
III.A.4.2. Selection of the divisor and derivative parameters for simultaneous determination of the five compounds.....	170
III.A.4.3. Analytical characteristics and method validation	171
III.A.4.3.1. Range and linearity	171

Contents

III.A.4.3.2. Accuracy	172
III.A.4.3.3. Precision.....	173
III.A.4.3.4. Selectivity.....	173
III.A.4.3.5. LOD and LOQ	173
III.A.4.4. Statistical analysis of the results	173
III.A.5. Conclusions	174

***Section B: Partial Least Square and Principal Components Regression
Chemometric Determinations of Cilastatin Sodium, Imipenem, Ciprofloxacin
Hydrochloride, Dexamethasone Sodium Phosphate and Paracetamol in
Human urine***

III.B.1. Introduction	186
III.B.2. Experimental	187
III.B.2.1. Apparatus	187
III.B.2.2. Software	187
III.B.2.3. Materials.....	187
III.B.2.3.1. Pure Standards.....	187
III.B.2.3.2. Reagents	188
III.B.2.3.3. Standard solutions	188
III.B.2.4. Procedure.....	188
III.B.2.4.1. Spectral characteristics of CIL, IMP, CIPRO, DEX and PAR	188
III.B.2.4.2. Calibration and validation sets	188
III.B.2.4.3. General procedure for PCR and PLS-2	189
III.B.2.4.4. Application to human urine.....	189
III.B.3. Results and Discussion.....	189
III.B.3.1. PCR and PLS-2 models.....	190
III.B.3.2. Application to human urine.....	192
III.B.4. Conclusions	192

Part IV: Selective Molecularly Imprinted Polymer-Based Potentiometric Determination of Enoxaparin Sodium

IV.A.1. Introduction.....	203
IV.A.2. Experimental.....	206
IV.A.2.1. Apparatus	206
IV.A.2.2. Materials	207
IV.A.2.2.1. Pure standards.....	207
IV.A.2.2.2. Pharmaceutical formulation.....	207
IV.A.2.2.3. Reagents.....	207
IV.A.2.2.4. Standard solutions.....	208
IV.A.2.2.4.1. ENOX stock aqueous solution (1.00×10^{-3} M)	208
IV.A.2.2.4.2. ENOX working aqueous solution (1.00×10^{-9} to 1.00×10^{-3} M).....	209
IV.A.2.3. Procedures.....	209
IV.A.2.3.1. Preparation of ENOX imprinted and non-imprinted polymer	209
IV.A.2.3.2. Characterization of ENOX imprinted and non-imprinted polymer	210
IV.A.2.3.2.1. Morphological characterization using SEM	210
IV.A.2.3.2.2. Characterization of FT-IR spectra	210
IV.A.2.3.2.3. Binding Experiments	210
IV.A.2.3.3. Fabrication of ENOX sensors	210
IV.A.2.3.4. Sensors assembly	211
IV.A.2.3.5. Direct potentiometric determination of ENOX in its pure sample	211
IV.A.2.3.6. Direct potentiometric determination of ENOX in pharmaceutical formulation..	212
IV.A.2.3.7. Study of experimental conditions	212
IV.A.2.3.7.1. Identification of slope, response time and operative life of the studied sensors	212
IV.A.2.3.7.2. Effect of pH and temperature.....	213
IV.A.2.3.7.3. Effect of foreign compounds	213
IV.A.3. Results and Discussion	214
IV.A.3.1. Sensors fabrication.....	214
IV.A.3.2. Characterization of MIP-modified electrodes.....	216

Contents

IV.A.3.2.1. Morphological characterization	216
IV.A.3.2.2. Characterization of FT-IR spectra	216
IV.A.3.2.2. Binding properties of ENOX imprinted polymer	217
IV.A.3.3. Performance and characteristics of the proposed sensors, sensors calibration and response time	219
IV.A.3.4. Effect of pH and temperature.....	220
IV.A.3.5. Sensors selectivity.....	220
IV.A.3.6. Potentiometric determination of ENOX in pharmaceutical formulation.....	221
IV.A.3.7. Figures of Merit	221
IV.A.4. Conclusions.....	222
 <i>References</i>	 233

List of Figures

Figure 1: Chromatogram (a) and MS spectrum (b) of OGN 1. Asterisk represents charge states	72
Figure 2: Chromatogram (a) and MS spectrum (b) of OGN 2. Asterisk represents charge states	72
Figure 3: Chromatogram (a) and MS spectrum (b) of OGN 3. Asterisk represents charge states	73
Figure 4: Chromatogram (a) and MS spectrum (b) of OGN 4. Asterisk represents charge states	73
Figure 5: Effect of different pH at 45°C on OGNs 1 (a), 2 (b), 3 (c), 4 (d) within 48 h	74
Figure 6: Chromatogram of OGN 1 samples in pH 7.0 before (a) and after heating at 90°C for 12 h (b)	75
Figure 7: Chromatogram of OGN 2 samples in pH 7.0 before (a) and after heating at 90°C for 12 h (b)	75
Figure 8: Chromatogram of OGN 3 samples in pH 7.0 before (a) and after heating at 90°C for 12 h (b)	76
Figure 9: Chromatogram of OGN 4 samples in pH 7.0 before (a) and after heating at 90°C for 12 h (b)	76
Figure 10: General degradation pathway of OGNs (a) full length OGN, (b) OGN with apurinic site, (c) OGN with terminal PS or PO, (d) shortmer (n-1)	77
Figure 11: Total number of potential degradation products at different pH within 48 h for OGNs 1 (a), 2 (b), 3 (c), 4 (d)	78
Figure 12: Effect of different pH at 90°C on OGNs 1 (a), 2 (b), 3 (c), 4 (d)	79
Figure 13: Plot of the pseudo-first-order kinetics of the degradation of OGNs 1 (a), 2 (b), 3 (c), 4 (d) at 90°C over different pH ranges within 48 h	79
Figure 14: Chromatogram (a) and MS spectrum (b) of OGN 1 at m/z 704.68 (z=9). Chromatogram (c) and MS spectrum (d) of OGN 1 at m/z 704.68 (z=9) after addition of 0.30% hydrogen peroxide for 4 h. Asterisk represents desulfurization fragments.	80
Figure 15: Chromatogram (a) and MS spectrum (b) of OGN 2 at m/z 720.68 (z=10). Chromatogram (c) and MS spectrum (d) of OGN 2 at m/z 720.68 (z=10) after addition of 0.30% hydrogen peroxide for 4 h. Asterisk represents desulfurization fragments	80
Figure 16: Chromatogram (a) and MS spectrum (b) of OGN 3 at m/z 729.87 (z=10). Chromatogram (c) and MS spectrum (d) of OGN 3 at m/z 729.87 (z=10) after addition of 0.30% hydrogen peroxide for 4 h. Asterisk represents desulfurization fragment	81
Figure 17: Chromatogram (a) and MS spectrum (b) of OGN 4 at m/z 684.79 (z=8). Chromatogram (c) and MS spectrum (d) of OGN 4 at m/z 684.79 (z=8) after addition of 0.30% hydrogen peroxide for 4 h. Asterisk represents desulfurization fragment	81
Figure 18: Effect of different concentrations of hydrogen peroxide on OGNs 1 (a), 2 (b), 3 (c), 4 (d)	82
Figure 19: Effect of 0.03% hydrogen peroxide on OGNs 1 (a), 2 (b), 3 (c), 4 (d) and formation of PO analogs within 24 h	82
Figure 20: Effect of 0.30% hydrogen peroxide on OGNs 1 (a), 2 (b), 3 (c), 4 (d) and formation of PO analogs within 24 h	83
Figure 21: Effect of 3.00% hydrogen peroxide on OGNs 1 (a), 2 (b), 3 (c), 4 (d) and formation of PO analogs within 24 h	83
Figure 22: Plot of the pseudo-first-order kinetics of the degradation of OGNs 1 (a), 2 (b), 3 (c), 4 (d) at concentrations of 0.03 and 0.30% of hydrogen peroxide	84
Figure 23: Chromatograms of blank samples (A), TIA at 1.00 ng mL ⁻¹ and IS TIA-D4 at 50.00 ng mL ⁻¹ as pure standards (B) and TIA in Stablon [®] tablets (C)	105